Cytek Biosciences, Inc.CTKBNASDAQ
Loading
Free Cash Flow Growth Recovery in ProgressRecovering
Percentile Rank65
3Y CAGR-13.7%
5Y CAGR-35.9%
Year-over-Year Change
Year-over-year free cash flow growth rate
3Y CAGR
-13.7%/yr
Quarterly compound
5Y CAGR
-35.9%/yr
Recent acceleration
Percentile
P65
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 61.08% |
| Q3 2025 | -209.94% |
| Q2 2025 | -50.51% |
| Q1 2025 | -189.21% |
| Q4 2024 | -91.19% |
| Q3 2024 | 148.11% |
| Q2 2024 | 50.01% |
| Q1 2024 | -58.06% |
| Q4 2023 | 241.18% |
| Q3 2023 | -33.52% |
| Q2 2023 | -279.26% |
| Q1 2023 | 664.27% |
| Q4 2022 | 95.16% |
| Q3 2022 | 20.00% |
| Q2 2022 | -376.46% |
| Q1 2022 | -154.43% |
| Q4 2021 | 2924.49% |
| Q3 2021 | 97.15% |
| Q2 2021 | -462.20% |
| Q1 2021 | -87.53% |
| Q4 2020 | 566.16% |
| Q3 2020 | 367.03% |
| Q2 2020 | -158.61% |
| Q1 2020 | 0.00% |